Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | DRD2 | P14416 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865544 | 0.90 | DRD2 (0.59) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL4868630 | 0.87 | HTR1A (0.55) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL4870640 | 0.86 | HTR1A (0.54) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL7418243 | 0.85 | DRD2 (0.67) | HTR1ASLC6A4DRD2HTR2AHTR6 | |
| SCHEMBL4862051 | 0.85 | DRD2 (0.59) | HTR1ASLC6A4DRD2SIGMAR1HTR6 | |
| SCHEMBL4865241 | 0.83 | DRD2 (0.59) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL4872140 | 0.82 | DRD2 (0.54) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL4873344 | 0.82 | DRD2 (0.56) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL10869314 | 0.82 | KDM4E (0.54) | HTR1ASLC6A4DRD2KDM4ELMNA | |
| SCHEMBL4871793 | 0.80 | DRD2 (0.44) | HTR1ASLC6A4DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | claimed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7148235-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | HTR1A 3/4885SLC6A4 21/4885DRD2 25/4885 |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | HTR1A 3/4885SLC6A4 20/4885DRD2 23/4885 |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | HTR1A 3/4885SLC6A4 20/4885DRD2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.